Application Note
*Optimal dilutions/concentrations should be determined by the researcher.
Application |
Recommended Dilution |
1:200 |
Assay dependent |
Assay dependent |
Not tested in other applications.
Calculated MW
Positive Control
The peptide used to generate this antibody is available for purchase (GTX28016).
Form
Liquid
Buffer
PBS, 0.2% Gelatin
Preservative
0.1% Sodium azide
Storage
Store as concentrated solution. Centrifuge briefly prior to opening vial. Store at 4ºC. DO NOT FREEZE.
Concentration
0.2 mg/ml (Please refer to the vial label for the specific concentration.)
Antigen Species
Human
Immunogen
Peptide mapping to the carboxy terminus of human p27.
Purification
Purified by affinity chromatography
Conjugation
Unconjugated
RRID
AB_369312
Note
For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.
Synonyms
cyclin dependent kinase inhibitor 1B , CDKN4 , KIP1 , MEN1B , MEN4 , P27KIP1
Cellular Localization
Nucleus , Cytoplasm , Endosome
Background
This gene encodes a cyclin-dependent kinase inhibitor, which shares a limited similarity with CDK inhibitor CDKN1A/p21. The encoded protein binds to and prevents the activation of cyclin E-CDK2 or cyclin D-CDK4 complexes, and thus controls the cell cycle progression at G1. The degradation of this protein, which is triggered by its CDK dependent phosphorylation and subsequent ubiquitination by SCF complexes, is required for the cellular transition from quiescence to the proliferative state. Mutations in this gene are associated with multiple endocrine neoplasia type IV (MEN4). [provided by RefSeq, Apr 2014]
Database
Research Area